Toll Free: 1-888-928-9744

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016', provides in depth analysis on Human Papillomavirus Protein E6 (E6) targeted pipeline therapeutics. 

The report provides comprehensive information on the Human Papillomavirus Protein E6 (E6), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
- The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Human Papillomavirus Protein E6 (E6) Overview 7 Therapeutics Development 8 Human Papillomavirus Protein E6 (E6) - Products under Development by Stage of Development 8 Human Papillomavirus Protein E6 (E6) - Products under Development by Therapy Area 9 Human Papillomavirus Protein E6 (E6) - Products under Development by Indication 10 Human Papillomavirus Protein E6 (E6) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Human Papillomavirus Protein E6 (E6) - Products under Development by Companies 13 Human Papillomavirus Protein E6 (E6) - Products under Development by Universities/Institutes 15 Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development 22 BioNTech AG 22 Cancer Research Technology Limited 23 Etubics Corporation 24 Genexine, Inc. 25 Inovio Pharmaceuticals, Inc. 26 MedImmune, LLC 27 Selecta Biosciences, Inc. 28 Tomegavax, Inc. 29 Transgene SA 30 Human Papillomavirus Protein E6 (E6) - Drug Profiles 31 Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ETBX-041 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 GX-188E - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 human papillomavirus [serotypes 16] vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 human papillomavirus vaccine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 INO-3106 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 INO-3112 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 PVX-01 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 SEL-701 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 TA-CIN - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 TG-4001 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 VGX-3100 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Vvax-001 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Human Papillomavirus Protein E6 (E6) - Dormant Projects 51 Human Papillomavirus Protein E6 (E6) - Discontinued Products 52 Human Papillomavirus Protein E6 (E6) - Featured News & Press Releases 53 Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress 53 Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 53 Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer 54 Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 55 Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial 56 Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress 57 Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients 58 Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology 59 Oct 30, 2014: Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial 59 Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 60 Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 60 Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 61 Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV 62 Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head & Neck Cancer 63 Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study 64 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 65 Disclaimer 66
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by BioNTech AG, H2 2016 22 Pipeline by Cancer Research Technology Limited, H2 2016 23 Pipeline by Etubics Corporation, H2 2016 24 Pipeline by Genexine, Inc., H2 2016 25 Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 26 Pipeline by MedImmune, LLC, H2 2016 27 Pipeline by Selecta Biosciences, Inc., H2 2016 28 Pipeline by Tomegavax, Inc., H2 2016 29 Pipeline by Transgene SA, H2 2016 30 Dormant Projects, H2 2016 51 Discontinued Products, H2 2016 52



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify